Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.
| Revenue (Most Recent Fiscal Year) | $0.20M |
| Net Income (Most Recent Fiscal Year) | $-26.17M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 649.39 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -25009.70% |
| Net Margin (Trailing 12 Months) | -25009.70% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -137.98% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.94 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.93 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 0.40 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.47 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.31 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.06 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.20 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 12.78M |
| Free Float | 9.16M |
| Market Capitalization | $87.02M |
| Average Volume (Last 20 Days) | 1.35M |
| Beta (Past 60 Months) | 0.89 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 28.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 23.28% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |